IMAT - ultrafast tomography for coronary artery disease Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John R Resseger who wrote (3497)	6/8/2000 12:28:00 AM
From: TA2K	of 3725

Read this post extra carefully Impact of AHA/ACC Statements on IMAT by: geoduc49 6/8/00 12:12 am Msg: 23320 of 23321 Major Statements on medical value/suggested uses for EBCT are published at infrequent intervals by these mainstream professional medical organizations and can have great impact on IMAT sales/stock price. The overly-cautious September, 1996 AHA Medical/Scientific Statement "Coronary Artery Calcification: Pathophysiology, Imaging Methods, and Clinical Implications" put the brakes on IMAT big time. It appeared that Heartscan Imaging was being positioned to take advantage of an enthusiastic Scientific Statement. Had the Statement been strongly positive, IMAT would have been rolling in dough instead of diluting stock to keep going. The 96 Statement was ambiguous on the-then present value of EBCT, recommended further study and against screening of asymptomatic populations; an expanded role for EBCT was put off into the future. It's now 4 years later and a lot of new data has been collected on the implications of coronary artery calcification. More prominent and respected members of the medical community are setting up EBCT clinics. The scanners and software have improved. IMAT management has done a great job with limited resources getting the word out that EBCT is second-to-none, cutting edge medical imaging technology with more FDA-approved uses for the scanner besides quantifying calcium. So, a convoluted, less-than-positive AHA/ACC Statement should cause no more than moderate damage to IMAT. A positive Statement should make IMAT a more valuable commodity as investor confidence is bolstered by realistic expectations that scanner sales are going to keep rising year-after-year. A bit of enthusiasm in that AHA/ACC Statement might even cause some investor fireworks around the 4th of July. Mark your calender: ACC EXPERT CONSENSUS DOCUMENTS IN PROGRESS Electron Beam Computed Tomography (EBCT) for Detecting Coronary Calcification (New) To be published July 1 JACC and July 4 Circulation

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next